Methamphetamine use while Breastfeeding
Drugs containing Methamphetamine: Desoxyn, Desoxyn Gradumet
Methamphetamine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Because there is no published experience with methamphetamine as a therapeutic agent during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Methamphetamine should not be used as a recreational drug by nursing mothers because it may impair their judgment and child care abilities. Methamphetamine and its metabolite, amphetamine, are detectable in breastmilk and infant's serum after abuse of methamphetamine by nursing mothers. However, these data are from random collections rather than controlled studies because of ethical considerations in administering recreational methamphetamine to nursing mothers. Other factors to consider are the possibility of positive urine tests in breastfed infants which might have legal implications, and the possibility of other harmful contaminants in street drugs. In mothers who abuse methamphetamine while nursing, withholding breastfeeding for 24 to 48 hours after the maternal dose has been recommended. However, breastfeeding is generally discouraged in mothers who are actively abusing amphetamines.
Maternal Levels. Two nursing mothers who were intravenous methamphetamine abusers collected milk samples just before methamphetamine injection and every 2 to 6 hours after injection for 24 hours. Because the drugs were illicit street drugs, the doses of methamphetamine were not known. Peak and average milk methamphetamine concentrations were about 160 mcg/L and 111 mcg/L in one woman and 610 mcg/L and 281 mcg/L in the other, respectively. Milk methamphetamine concentrations fell with half-lives of 13.6 and 7.4 hours, respectively. Amphetamine, thought to be derived from metabolism of methamphetamine, was present in relatively constant concentrations in the milk of both mothers, averaging 4 and 15 mcg/L, respectively. The authors estimated that the infants would have received 16.7 and 42.2 mcg/kg per day of methamphetamine and 0.8 and 2.5 mcg/kg per day of amphetamine, respectively. These estimated mg/kg infant doses of methamphetamine are lower than therapeutic doses of the equipotent dextroamphetamine for older children with attention deficit hyperactivity disorder. However, this is not evidence of safety for breastfed infants because the data on these two women can not be extrapolated to other methamphetamine abusers.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
A 2-month-old infant whose mother used illicit street methamphetamine recreationally by nasal inhalation was found dead 8 hours after a small amount of breastfeeding and ingestion of 120 to 180 mL of formula. The infant's serum methamphetamine concentration on autopsy was 39 mcg/L. Although the infant's mother was convicted of child endangerment for the use of methamphetamine during breastfeeding, the role that methamphetamine played in the infant's death has been questioned because of the low infant serum methamphetamine concentration and the mother's alleged minimal breastfeeding.
Effects on Lactation and Breastmilk
A single oral dose of 0.2 mg/kg to a maximum of 17.5 mg of d-methamphetamine was given to 6 subjects (4 male and 2 female). Serum prolactin concentrations were unchanged over a period of 300 minutes after the dose.
In 2 papers by the same authors, 20 women with normal physiologic hyperprolactinemia were studied on days 2 or 3 postpartum. Eight received dextroamphetamine 7.5 mg intravenously, 6 received 15 mg intravenously and 6 who served as controls received intravenous saline. The 7.5 mg dose reduced serum prolactin by 25 to 32% compared to control, but the difference was not statistically significant. The 15 mg dose significantly decreased serum prolactin by 30 to 37% at times after the infusion. No assessment of milk production was presented. The authors also quoted data from another study showing that a 20 mg oral dose of dextroamphetamine produced a sustained suppression of serum prolactin by 40% in postpartum women.
A study compared 31 methamphetamine-dependent subject to 23 non-dependent subjects. The serum prolactin concentrations in the methamphetamine-dependent subjects were elevated at days 2 and 30 of abstinence. The elevation was greater in women than in men. The maternal prolactin level in a mother with established lactation may not affect her ability to breastfeed.
In a retrospective Australian study, mothers who used intravenous amphetamines during pregnancy were less likely to be breastfeeding their newborn infants at discharge than mothers who abused other drugs (27% vs 42%). The cause of this difference was not determined.
A prospective, multicenter study followed mothers who used methamphetamine prenatally (n = 204) to those who did not (n = 208). Mothers who used methamphetamine were less likely to breastfeed their infants (38%) at hospital discharge than those who did not use methamphetamine (76%).
Alternate Drugs to Consider
1. Bartu A, Dusci LJ, Ilett KF . Transfer of methylamphetamine and amphetamine into breast milk following recreational use of methylamphetamine. Br J Clin Pharmacol. 2009;67:455-9. PMID: 19371319
2. ACOG Committee on Health Care for Underserved Women. Committee Opinion No. 479: Methamphetamine abuse in women of reproductive age. Obstet Gynecol. 2011;117:751-5. PMID: 21343793
3. Oei JL, Kingsbury A, Dhawan A et al. Amphetamines, the pregnant woman and her children: A review. J Perinatol. 2012;32:737-47. PMID: 22652562
4. AAP Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129:e827-41. PMID: 22371471
5. Wong S, Ordean A, Kahan M. SOGC clinical practice guidelines: Substance use in pregnancy: No. 256, April 2011. Int J Gynaecol Obstet. 2011;114:190-202. PMID: 21870360
6. Ariagno R, Karch SB, Middleberg R et al. Methamphetamine ingestion by a breast-feeding mother and her infant's death: People v Henderson. JAMA. 1995;274:215. Letter. PMID: 7609223
7. Green LS. People v Henderson: the prosecution responds. JAMA. 1996;275:183-4. Letter. PMID: 8604164
8. Gouzoulis-Mayfrank E, Thelen B, Habermeyer E et al. Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl). 1999;142:41-50. PMID: 10102781
9. DeLeo V, Cella SG, Camanni F, Genazzani AR, Muller EE. Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia. Horm Metab Res. 1983;15:439-43. PMID: 6642414
10. Petraglia F, De Leo V, Sardelli S et al. Prolactin changes after administration of agonist and antagonist dopaminergic drugs in puerperal women. Gynecol Obstet Invest. 1987;23:103-9. PMID: 3583091
11. Zorick T, Mandelkern MA, Lee B et al. Elevated plasma prolactin in abstinent methamphetamine-dependent subjects. Am J Drug Alcohol Abuse. 2011;37:62-7. PMID: 21142706
12. Oei JL, Abdel-Latif ME, Clark R et al. Short-term outcomes of mothers and infants exposed to antenatal amphetamines. Arch Dis Child Fetal Neonatal Ed. 2010;95:F36-F41. PMID: 19679891
13. Shah R, Diaz SD, Arria A et al. Prenatal methamphetamine exposure and short-term maternal and infant medical outcomes. Am J Perinatol. 2012;29:391-400. PMID: 22399214
CAS Registry Number
Central Nervous System Stimulants
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.